This 3-Stock Portfolio Is a Safe Bet on a Coronavirus Vaccine
As of Sept. 15, there have been nearly 30 million confirmed cases of COVID-19 around the world, and over 930,000 deaths have been attributed to the virus. Pharmaceutical and biotech companies are scrambling to develop an effective vaccine against the deadly disease in order to save lives and allow economies to reopen safely. As a result of this race, picking the vaccine stocks that will likely be "winners" has become a hot topic in the investment world.
There are many reasons why efforts to develop and distribute a coronavirus vaccine may not proceed as expected, including clinical trial failures, serious adverse events after receiving the vaccine candidate, and skepticism about potential long-term side effects. While it's always good for investors to diversify their capital among companies that are most likely to advance a potential vaccine, they should also hedge their bet with coronavirus treatment stocks if vaccine trials go horribly wrong. So, let us examine a three-stock coronavirus basket that's a safe bet for investors interested in getting in on all the action.
Image source: Getty Images.
Source Fool.com
